https://european-biotechnology.com/wp-content/uploads/2024/04/Drooms_Whitepaper.png360640Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2016-10-17 16:12:172016-10-17 16:12:1714 Must-Haves to Boost the Efficiency of Your Data Room
Apitope said it has regained global rights to its IL-10-bolstering vaccination ATX-MS-1467 for remitting-relapsing multiple sclerosis from Merck KGaA. A 2009 contract forsaw that Merck will take over commercialisation cost following Phase II testing. Phase II data are due to be published in Q4/2016.
https://european-biotechnology.com/wp-content/uploads/2024/04/news_domain_model_tag_add.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2016-10-17 10:23:592016-10-17 10:23:59Merck drops MS collaboration with Apitope
Oslo-based Nordic Nanovector has elected Joanna Horobin to its board as Non-executive Board Director. She replaces Renee Tannenbaum who stepped down from the board for personal reasons.
https://european-biotechnology.com/wp-content/uploads/2024/04/joanna-horobin.jpg286254h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-17 07:21:002016-10-17 07:21:00Nordic Nanovector: New on board
German mRNA company Curevac AG has appointed Pierre Kemula as Chief Financial Officer. Kemula joins Curevac from medtech firm Pixium Vision, where he was also responsible for financial activities.
https://european-biotechnology.com/wp-content/uploads/2024/04/swegen-bio.png4580h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-13 17:14:002016-10-13 17:14:00Curevac: In command of finance
The European Patent Office’s decision to speed up examination of patent applications to 12 months without any transition period is set to ruin biotech SMEs financially and may send a blocking signal to innovators.
The Royal Swedish Academy of Sciences has awarded the Tobias Prize 2016 to stem cell researcher David Bryder of Lund University for his groundbreaking hematopoietic stem cell discoveries.
With globally at least 30 million of cases per year, sepsis is a major health threat for which a specific adjunctive sepsis therapy beyond antimicrobial treatment, surgical source control and supportive intensive care measure is still missing.
https://european-biotechnology.com/wp-content/uploads/2024/04/EBM_Spring_16_Garlich_von_Essen_01.jpg450800h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-10 14:44:002016-10-10 14:44:00Why new approaches that target sepsis need support
Roche is making up lost ground in immuno-oncology. The Swiss company’s PD-L1 directed immunotherapy atezolizumab is more effective in combatting lung cancer than standard chemotherapy.
Well, those bloody idiots in the UK managed to do it talk themselves from decades of hysteria about straight bananas (entirely fabricated by one B Johnson during his time as a journalist in Brussels) into actually voting to leave.
https://european-biotechnology.com/wp-content/uploads/2024/04/claire-skentelbery.jpg450800h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-09 13:46:002016-10-09 13:46:00In the Brexshit
14 Must-Haves to Boost the Efficiency of Your Data Room
Sponsored PublicationsStop wasting time with data room software that doesn’t really improve your workflow.
Merck drops MS collaboration with Apitope
Latest NewsApitope said it has regained global rights to its IL-10-bolstering vaccination ATX-MS-1467 for remitting-relapsing multiple sclerosis from Merck KGaA. A 2009 contract forsaw that Merck will take over commercialisation cost following Phase II testing. Phase II data are due to be published in Q4/2016.
Nordic Nanovector: New on board
AppointmentsCurevac: In command of finance
AppointmentsGerman mRNA company Curevac AG has appointed Pierre Kemula as Chief Financial Officer. Kemula joins Curevac from medtech firm Pixium Vision, where he was also responsible for financial activities.
EPO rules threaten biotech industry
Latest NewsThe European Patent Office’s decision to speed up examination of patent applications to 12 months without any transition period is set to ruin biotech SMEs financially and may send a blocking signal to innovators.
Laurels for stem cell groundbreaker
AppointmentsWhy new approaches that target sepsis need support
OpinionWith globally at least 30 million of cases per year, sepsis is a major health threat for which a specific adjunctive sepsis therapy beyond antimicrobial treatment, surgical source control and supportive intensive care measure is still missing.
Roche’s NSLC mAb outperforms chemo
Latest NewsRoche is making up lost ground in immuno-oncology. The Swiss company’s PD-L1 directed immunotherapy atezolizumab is more effective in combatting lung cancer than standard chemotherapy.
In the Brexshit
OpinionWell, those bloody idiots in the UK managed to do it talk themselves from decades of hysteria about straight bananas (entirely fabricated by one B Johnson during his time as a journalist in Brussels) into actually voting to leave.
Synvina: BASF and Avantium join forces
Latest NewsThe new joint venture Synvina is positioned in the market for drop-in bioplastics with advanced product characteristics.